Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

381 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Dramatic response to crizotinib in ROS1 fluorescent in situ hybridization- and immunohistochemistry-positive lung adenocarcinoma: a case series.
Chiari R, Buttitta F, Iacono D, Bennati C, Metro G, Di Lorito A, Iezzi M, Tiseo M, Mazzoni F, Cappuzzo F, Marchetti A, Crinò L. Chiari R, et al. Among authors: tiseo m. Clin Lung Cancer. 2014 Nov;15(6):470-4. doi: 10.1016/j.cllc.2014.06.004. Epub 2014 Jun 24. Clin Lung Cancer. 2014. PMID: 25087901 No abstract available.
Comparison between epidermal growth factor receptor (EGFR) gene expression in primary non-small cell lung cancer (NSCLC) and in fine-needle aspirates from distant metastatic sites.
Bozzetti C, Tiseo M, Lagrasta C, Nizzoli R, Guazzi A, Leonardi F, Gasparro D, Spiritelli E, Rusca M, Carbognani P, Majori M, Franciosi V, Rindi G, Ardizzoni A. Bozzetti C, et al. Among authors: tiseo m. J Thorac Oncol. 2008 Jan;3(1):18-22. doi: 10.1097/JTO.0b013e31815e8ba2. J Thorac Oncol. 2008. PMID: 18166836 Free article.
An expanded access program of erlotinib (Tarceva) in patients with advanced non-small cell lung cancer (NSCLC): data report from Italy.
Tiseo M, Gridelli C, Cascinu S, Crinò L, Piantedosi FV, Grossi F, Brandes AA, Labianca R, Siena S, Amoroso D, Belvedere O, Valentino B, Bearz A, Venturino P, Ardizzoni A. Tiseo M, et al. Lung Cancer. 2009 May;64(2):199-206. doi: 10.1016/j.lungcan.2008.09.001. Epub 2008 Oct 31. Lung Cancer. 2009. PMID: 18951651 Clinical Trial.
Correlation of cytidine deaminase polymorphisms and activity with clinical outcome in gemcitabine-/platinum-treated advanced non-small-cell lung cancer patients.
Tibaldi C, Giovannetti E, Tiseo M, Leon LG, D'Incecco A, Loosekoot N, Bartolotti M, Honeywell R, Cappuzzo F, Ardizzoni A, Peters GJ. Tibaldi C, et al. Among authors: tiseo m. Ann Oncol. 2012 Mar;23(3):670-677. doi: 10.1093/annonc/mdr280. Epub 2011 Jun 7. Ann Oncol. 2012. PMID: 21652582 Free article.
Pemetrexed versus pemetrexed and carboplatin as second-line chemotherapy in advanced non-small-cell lung cancer: results of the GOIRC 02-2006 randomized phase II study and pooled analysis with the NVALT7 trial.
Ardizzoni A, Tiseo M, Boni L, Vincent AD, Passalacqua R, Buti S, Amoroso D, Camerini A, Labianca R, Genestreti G, Boni C, Ciuffreda L, Di Costanzo F, de Marinis F, Crinò L, Santo A, Pazzola A, Barbieri F, Zilembo N, Colantonio I, Tibaldi C, Mattioli R, Cafferata MA, Camisa R, Smit EF. Ardizzoni A, et al. Among authors: tiseo m. J Clin Oncol. 2012 Dec 20;30(36):4501-7. doi: 10.1200/JCO.2012.43.6758. Epub 2012 Oct 29. J Clin Oncol. 2012. PMID: 23109689 Clinical Trial.
Activity of the EGFR-HER2 dual inhibitor afatinib in EGFR-mutant lung cancer patients with acquired resistance to reversible EGFR tyrosine kinase inhibitors.
Landi L, Tiseo M, Chiari R, Ricciardi S, Rossi E, Galetta D, Novello S, Milella M, D'Incecco A, Minuti G, Tibaldi C, Salvini J, Facchinetti F, Haspinger ER, Cortinovis D, Santo A, Banna G, Catino A, GiajLevra M, Crinò L, de Marinis F, Cappuzzo F. Landi L, et al. Among authors: tiseo m. Clin Lung Cancer. 2014 Nov;15(6):411-417.e4. doi: 10.1016/j.cllc.2014.07.002. Epub 2014 Aug 16. Clin Lung Cancer. 2014. PMID: 25242668 Free article.
381 results